---
title: "Jilin Province Huinan Changlong Bio-Pharmacy FY26 H1 profit attributable to shareholders rises 19.25% to RMB 122.84 million; revenue slips 0.87% to RMB 435.05 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295947668.md"
description: "Jilin Province Huinan Changlong Bio-Pharmacy reported FY26 H1 profit attributable to shareholders of RMB 122.84 million, a 19.25% increase year-on-year, despite a slight 0.87% revenue decline to RMB 435.05 million. Operating profit rose to RMB 151.77 million, driven by an expanded gross margin of 83.9% due to lower costs. The company maintains a zero gearing ratio with RMB 234.22 million in cash. Operational upgrades included automation enhancements and the commercial launch of the oral liquid workshop following GMP inspection."
datetime: "2026-08-14T14:23:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295947668.md)
  - [en](https://longbridge.com/en/news/295947668.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295947668.md)
generator: "portal-rs"
---

# Jilin Province Huinan Changlong Bio-Pharmacy FY26 H1 profit attributable to shareholders rises 19.25% to RMB 122.84 million; revenue slips 0.87% to RMB 435.05 million

-   Jilin Province Huinan Changlong Bio-Pharmacy posted profit attributable to shareholders of RMB 122.84 million, up 19.25% year-on-year. \* Turnover edged down 0.1% to RMB 435.05 million, while profit from operations climbed to RMB 151.77 million. \* Gross margin widened to 83.9%, attributed to lower production and material costs. \* Gearing ratio was about 0% with no short-term bank borrowings; cash and cash equivalents rose to RMB 234.22 million. \* Upgrades added automation across solid-dose and packaging lines; the oral liquid workshop entered commercial operation following an August 2025 GMP inspection. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jilin Province Huinan Changlong Bio-Pharmacy Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260814-12285711), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [08049.HK](https://longbridge.com/en/quote/08049.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Huinan Changlong Bio-Pharmacy schedules board meeting to review interim results](https://longbridge.com/en/news/294813398.md)
- [LongBio Pharma Calls September 2026 EGM to Approve New Non-Executive Director](https://longbridge.com/en/news/296631538.md)
- [SinoMab Seeks Shareholder Approval to Sell Suzhou Industrial Property for RMB280 Million](https://longbridge.com/en/news/296542794.md)
- [Jiangsu Recbio Clarifies Board Composition and Committee Leadership](https://longbridge.com/en/news/296390996.md)
- [01:21 ETGC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan](https://longbridge.com/en/news/296739342.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**